1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Θετικών Επιστημών
  4. Τμήμα Χημείας
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά). ΧΗΜ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/10554
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDerdemezis, C. S.en
dc.contributor.authorFilippatos, T. D.en
dc.contributor.authorVoulgari, P. V.en
dc.contributor.authorTselepis, A. D.en
dc.contributor.authorDrosos, A. A.en
dc.contributor.authorKiortsis, D. N.en
dc.date.accessioned2015-11-24T16:57:14Z-
dc.date.available2015-11-24T16:57:14Z-
dc.identifier.issn0767-3981-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/10554-
dc.rightsDefault Licence-
dc.subjectadiponectinen
dc.subjectanti-tnfen
dc.subjectinfliximaben
dc.subjectleptinen
dc.subjectrheumatoid arthritisen
dc.subjectantitumor-necrosis-factoren
dc.subjectalpha monoclonal-antibodyen
dc.subjectpulse-wave velocityen
dc.subjecttnf-alphaen
dc.subjectdisease-activityen
dc.subjectankylosing-spondylitisen
dc.subjectinsulin-resistanceen
dc.subjectmetabolic syndromeen
dc.subjectserum-levelsen
dc.subjecttherapyen
dc.titleEffects of a 6-month infliximab treatment on plasma levels of leptin and adiponectin in patients with rheumatoid arthritisen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primaryDOI 10.1111/j.1472-8206.2009.00717.x-
heal.identifier.secondary<Go to ISI>://000269577700012-
heal.identifier.secondaryhttp://onlinelibrary.wiley.com/store/10.1111/j.1472-8206.2009.00717.x/asset/j.1472-8206.2009.00717.x.pdf?v=1&t=h0f7sfo5&s=60eb7c1bdf0627cb54424a7fcfb391f497ea4e22-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Θετικών Επιστημών. Τμήμα Χημείαςel
heal.publicationDate2009-
heal.abstractPatients with rheumatoid arthritis (RA) appear to have increased plasma levels of leptin and adiponectin. These adipokines may be implicated in the pathophysiology of RA. Tumour necrosis factor alpha (Tau NF-alpha) is a potential modulator of adipokines. The effects of long-term anti-TNF treatment on plasma levels of leptin and adiponectin are not clear. The aim of this study was to assess the effects of 6-month anti-TNF treatment (infliximab) on leptin and adiponectin plasma levels in RA patients. Thirty women with RA were included in the study. Patients with diabetes mellitus, any endocrine disorder or receiving any hypolipidemic or antidiabetic medication were not included. Thirty healthy age- and body mass index-matched women served as controls. Plasma levels of leptin and adiponectin were measured with enzyme immunoassay methods prior to and after the 6-month treatment with infliximab. Mean age and disease duration of patients were 51.8 +/- 14.4 and 12.2 +/- 6.7 years, respectively. Body weight did not change significantly over the 6-month period. Plasma levels of leptin and adiponectin were higher in patients than controls and did not change significantly after 6-month treatment. Interestingly, in the tertile of patients with the highest baseline adiponectin concentrations, adiponectin levels were significantly reduced (P < 0.05). Infliximab treatment did not change plasma levels of leptin and adiponectin after 6-month treatment in the whole study population. However, a reduction of adiponectin levels was observed in patients with higher baseline adiponectin levels.en
heal.journalNameFundamental & Clinical Pharmacologyen
heal.journalTypepeer reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά). ΧΗΜ

Show simple item record
Files in This Item:
File Description SizeFormat 
Derdemezis-2009-Effects of a 6-month.pdf76.38 kBAdobe PDFView/Open    Request a copy
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons